359 related articles for article (PubMed ID: 22035209)
1. Endogenous migration modulators as parent compounds for the development of novel cardiovascular and anti-inflammatory drugs.
Poller W; Rother M; Skurk C; Scheibenbogen C
Br J Pharmacol; 2012 Apr; 165(7):2044-58. PubMed ID: 22035209
[TBL] [Abstract][Full Text] [Related]
2. Moving targets: cell migration inhibitors as new anti-inflammatory therapies.
Mackay CR
Nat Immunol; 2008 Sep; 9(9):988-98. PubMed ID: 18711436
[TBL] [Abstract][Full Text] [Related]
3. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
4. Microfilaments in cellular and developmental processes.
Wessells NK; Spooner BS; Ash JF; Bradley MO; Luduena MA; Taylor EL; Wrenn JT; Yamada K
Science; 1971 Jan; 171(3967):135-43. PubMed ID: 5538822
[TBL] [Abstract][Full Text] [Related]
5. Two faces of inflammation: an immunopharmacological view.
Moilanen E
Basic Clin Pharmacol Toxicol; 2014 Jan; 114(1):2-6. PubMed ID: 24286361
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic anti-inflammatory potential of formyl-peptide receptor agonists.
Dufton N; Perretti M
Pharmacol Ther; 2010 Aug; 127(2):175-88. PubMed ID: 20546777
[TBL] [Abstract][Full Text] [Related]
7. Intestinal immunomodulation. Role of regulative peptides and promising pharmacological activities.
Motilva V; Talero E; Calvo JR; Villegas I; Alarcón-de-la-Lastra C; Sánchez-Fidalgo S
Curr Pharm Des; 2008; 14(1):71-95. PubMed ID: 18220820
[TBL] [Abstract][Full Text] [Related]
8. Multi-target drugs to address multiple checkpoints in complex inflammatory pathologies: evolutionary cues for novel "first-in-class" anti-inflammatory drug candidates: a reviewer's perspective.
Mathew G; Unnikrishnan MK
Inflamm Res; 2015 Oct; 64(10):747-52. PubMed ID: 26186905
[TBL] [Abstract][Full Text] [Related]
9. PI3K isoforms as drug targets in inflammatory diseases: lessons from pharmacological and genetic strategies.
Harris SJ; Foster JG; Ward SG
Curr Opin Investig Drugs; 2009 Nov; 10(11):1151-62. PubMed ID: 19876783
[TBL] [Abstract][Full Text] [Related]
10. Discovery of novel anti-inflammatory drug-like compounds by aligning in silico and in vivo screening: the nitroindazolinone chemotype.
Marrero-Ponce Y; Siverio-Mota D; Gálvez-Llompart M; Recio MC; Giner RM; García-Domènech R; Torrens F; Arán VJ; Cordero-Maldonado ML; Esguera CV; de Witte PA; Crawford AD
Eur J Med Chem; 2011 Dec; 46(12):5736-53. PubMed ID: 22000935
[TBL] [Abstract][Full Text] [Related]
11. Target-Based Small Molecule Drug Discovery Towards Novel Therapeutics for Inflammatory Bowel Diseases.
Li Y; Chen J; Bolinger AA; Chen H; Liu Z; Cong Y; Brasier AR; Pinchuk IV; Tian B; Zhou J
Inflamm Bowel Dis; 2021 Nov; 27(Suppl 2):S38-S62. PubMed ID: 34791293
[TBL] [Abstract][Full Text] [Related]
12. Directional migration of leukocytes: their pathological roles in inflammation and strategies for development of anti-inflammatory therapies.
Geng JG
Cell Res; 2001 Jun; 11(2):85-8. PubMed ID: 11453550
[TBL] [Abstract][Full Text] [Related]
13. Side effect profile similarities shared between antidepressants and immune-modulators reveal potential novel targets for treating major depressive disorders.
Sun Y; Narayan VA; Wittenberg GM
BMC Pharmacol Toxicol; 2016 Oct; 17(1):47. PubMed ID: 27765060
[TBL] [Abstract][Full Text] [Related]
14. Developing microRNA therapeutics: approaching the unique complexities.
Jackson AL; Levin AA
Nucleic Acid Ther; 2012 Aug; 22(4):213-25. PubMed ID: 22913594
[TBL] [Abstract][Full Text] [Related]
15. Will iPSC-cardiomyocytes revolutionize the discovery of drugs for heart disease?
Bruyneel AA; McKeithan WL; Feyen DA; Mercola M
Curr Opin Pharmacol; 2018 Oct; 42():55-61. PubMed ID: 30081259
[TBL] [Abstract][Full Text] [Related]
16. A systems biology strategy for predicting similarities and differences of drug effects: evidence for drug-specific modulation of inflammation in atherosclerosis.
Kleemann R; Bureeva S; Perlina A; Kaput J; Verschuren L; Wielinga PY; Hurt-Camejo E; Nikolsky Y; van Ommen B; Kooistra T
BMC Syst Biol; 2011 Aug; 5():125. PubMed ID: 21838869
[TBL] [Abstract][Full Text] [Related]
17. Discovery of Novel CXCR2 Inhibitors Using Ligand-Based Pharmacophore Models.
Ha H; Debnath B; Odde S; Bensman T; Ho H; Beringer PM; Neamati N
J Chem Inf Model; 2015 Aug; 55(8):1720-38. PubMed ID: 26153616
[TBL] [Abstract][Full Text] [Related]
18. Animal Models of Inflammation for Screening of Anti-inflammatory Drugs: Implications for the Discovery and Development of Phytopharmaceuticals.
Patil KR; Mahajan UB; Unger BS; Goyal SN; Belemkar S; Surana SJ; Ojha S; Patil CR
Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31491986
[TBL] [Abstract][Full Text] [Related]
19. Targeting dysfunctional beta-cell signaling for the potential treatment of type 1 diabetes mellitus.
Fenske RJ; Kimple ME
Exp Biol Med (Maywood); 2018 Mar; 243(6):586-591. PubMed ID: 29504478
[TBL] [Abstract][Full Text] [Related]
20. Anti-Inflammatory Drugs and Herbs with Special Emphasis on Herbal Medicines for Countering Inflammatory Diseases and Disorders - A Review.
Yatoo MI; Gopalakrishnan A; Saxena A; Parray OR; Tufani NA; Chakraborty S; Tiwari R; Dhama K; Iqbal HMN
Recent Pat Inflamm Allergy Drug Discov; 2018; 12(1):39-58. PubMed ID: 29336271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
